about us

Filament Health was founded by experts in botanical extraction and commercialization.

Meet The Team
A person cultivating psilocybin mushrooms in a lab
founding story

We honed our expertise at Mazza Innovation, a natural extraction startup, which our team scaled from pre-seed to an exit in 2018. At Mazza, we developed and commercialized patent-protected extraction technologies at a 35,000 ft2 commercial-scale GMP facility.

After selling Mazza, it became clear that our expertise was needed in a new area. Ben Lightburn, Filament Health’s CEO and Co-Founder, took note of the growing global mental health crisis. He believed that psychedelics could help, and that natural psychedelics would be the preferred choice.


Ben also recognized his unique position - he had the skills and experience to develop natural psychedelic drugs. By combining his background as entrepreneur with the botanical extraction expertise of the former Mazza Innovation team, Filament Health was created.


Psilocybin Mushrooms on a drying rack in the Filament Health labratoy
OUR TEAM

Global Experts in Botanical Extraction and Commercialization

Scaled Mazza Innovation from pre-seed to $26M sale to Sensient Technologies in 2018.
Developed and commercialized patent-protected, botanical extraction technology at commercial-scale 35,000 sq. ft. GMP facility.

management

Benjamin Lightburn
Chief Executive Officer and Co-Founder
B.Sc (Physics), MBA.    *CEO, Mazza Innovation

Proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies

Lisa Ranken
Chief Operating Officer
P.Eng, M.Eng.     *VP, Operations, Mazza Innovation

Operational and leadership expertise in rapidly growing industries

Warren Duncan
Chief Financial Officer
CPA, B.Comm

Experienced in audit, accounting, capital markets, M&A and equity financing

Ryan Moss
Chief Science Officer
M. Analytical Chemistry *Director of Research at Mazza Innovation

Expert in the field of botanical extraction, purification, standardization

Andry Tjahyana
Vice President, Business Development
BBA      *VP, Business Development, Mazza Innovation

+25 years in B2B business development. Former senior executive of several pharmaceutical and natural product organizations

Anna Cordon
Director of Communications
BA

12+ years of experience leading marketing and communications for global organizations.

Taran Grey
Director of Intellectual Property
BA

Extensive patent and trademark portfolio experience in healthcare, technology and other diversified industries

Beatriz Ramos
Director of Quality
B.Sc.      *Manager, Quality Assurance, Mazza Innovation

Quality management, regulatory compliance, and attaining third-party certification

Sara Burke
Head of Global Partnerships
MBA, BA

15 years in corporate partnership development and brand strategy

Jeff Fellows
Head of Regulatory
B.Sc.

30 years of drug development experience leading regulatory development efforts from pre-IND to post-approval

board

Greg Mills
Director, Board Chair
B.Sc.

Former Managing Director, Head Global Equities, RBC Capital Markets Chairman, Sundial Growers Inc. NEO Exchange, Independent Board member

Maureen O’Connell
Director, Audit Committee Chair
Certified Public Accountant

Previously Audit Committee Chair of Sucampo Pharma (NASDAQ: SCMP) until its sale in 2018 Formerly CFO of Scholastic Board Member of Harte Hanks, Beazer Homes

Jon Conlin
Director

Partner at Fasken Corporate and commercial lawyer specializing in companies in the technology and health sciences sectors including venture capitalists and start-ups

Benjamin Lightburn
Director
B.Sc (Physics), MBA.    *CEO, Mazza Innovation

Proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies

Chris Wagner
Director
B.Sc. (Organic Chemistry), Accredited Director (UK and Ireland)

Over 25 years of experience in the life sciences industry, most recently as CEO and Director of both private and public companies Led Prozac and Zyprexa teams at Eli Lilly Founder and VP at Aspreva Pharmaceuticals

Konstantin Adamsky
Director
Ph.D

Chief Operating Officer of Negev Capital, demonstrated track record in pharmaceutical R&D. Served as a VP Operations and Technology at Levco Pharmaceuticals Ltd, CEO and VP Operations at Regenera Pharma LTD, and Director and co-CEO at Targia Pharmaceuticals.

Advisory council

Joshua Woolley
Medical Advisor
BSc, Ph.D, M.D.

Associate Professor at UCSF; PI and Director of UCSF’s BAND Lab; Director of the TrPR Program at UCSF

Jeff Chilton
Advisor

Founder of Nammex, the first company to supply medicinal mushroom extracts to the nutritional supplement industry.

Research & industry partners

Filament Foundation

We are doing everything in our power to advance our mission of seeing safe, natural psychedelics in the hands of everyone who needs them, as soon as possible.

A person in a lab coat using medical apparatus

Meaningful change requires the development of an ecosystem of players who are dedicated to making accessible psychedelic therapy a reality.

With this in mind, the founders of Filament Health pledged 10% of their founder’s shares to a charitable foundation controlled by a majority of non-Filament insiders to support non-corporate, value-aligned projects.

filament foundation board
Karen Mahon

Former Managing Director: Greenpeace Canada and Public Outreach USA

Joel Solomon

Founder, Renewal Funds

Tom Kineshanko

Benjamin Lightburn
Chair
B.Sc (Physics), MBA.    *CEO, Mazza Innovation

Proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies

Social responsibility

Filament Health is committed to ethical and sustainable practices throughout our drug development platform.

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.